Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated Vasculitis

Xueqin Wu¹, Yong Zhong², Ting Meng², Joshua Daniel Ooi²³, Peter J. Eggenhuizen³, Rong Tang², Wannian Nie², Xiangcheng Xiao², Jian Sun¹, Xiang Ao²* and Hao Zhang¹*

¹ Department of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, China, ² Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China, ³ Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia

Background: A significant proportion of anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis eventually progresses to end-stage renal disease (ESRD) thus requiring long-term dialysis. There is no consensus about which dialysis modality is more recommended for those patients with associated vasculitis (AAV-ESRD). The primary objective of this study was to compare patient survival in patients with AAV-ESRD treated with hemodialysis (HD) or peritoneal dialysis (PD).

Methods: This double-center retrospective cohort study included dialysis-dependent patients who were treated with HD or PD. Clinical data were collected under standard format. The Birmingham vasculitis activity score (BVAS) was used to evaluate disease activity at diagnosis and organ damage was assessed using the vasculitis damage index (VDI) at dialysis initiation.

Results: In total, 85 patients were included: 64 with hemodialysis and 21 with peritoneal dialysis. The patients with AAV-PD were much younger than the AAV-HD patients (48 vs. 62, \( P < 0.01 \)) and more were female (76.2 vs. 51.6%, \( P = 0.05 \)). The laboratory data were almost similar. The comorbidities, VDI score, and immuno-suppressive therapy at dialysis initiation were almost no statistical difference. Patient survival rates between HD and PD at 1 year were 65.3 vs. 90% (\( P = 0.062 \)), 3 year were 59.6 vs. 90% (\( P < 0.001 \)), and 5 years were 59.6 vs. 67.5% (\( P = 0.569 \)). The overall survival was no significant difference between the two groups (\( P = 0.086 \)) and the dialysis modality (HD or PD) was not shown to be an independent predictor for all-cause death (hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.31–1.7; \( P = 0.473 \)). Cardio-cerebrovascular events were the main cause of death among AAV-HD patients while infection in patients with AAV-PD.

Conclusion: These results provide real-world data that the use of either hemodialysis or peritoneal dialysis modality does not affect patient survival for patients with AAV-ESRD who need long-term dialysis.

Keywords: AAV (ANCA-associated vasculitis), ESRD (end-stage renal disease), hemodialysis (HD), peritoneal dialysis (PD), patient survival
INTRODUCTION

Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN) is one of the major complications of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The myeloperoxidase (MPO)-ANCA AAV which is the most common subtype among Chinese AAV patients is more likely to get kidney involvement than proteinase 3 (PR3)-ANCA AAV (1). The renal outcomes in patients with AAV have improved significantly over the past decades, however, a significant proportion (up to 20–30%) of them eventually progress to end-stage renal disease (ESRD) requiring dialysis, especially in patients without timely and adequate immunosuppressive therapy at the initial presentation (2, 3).

Renal replacement therapy (RRT) including hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation (KT) is the established treatment for those patients with AAV-ESRD and it seems that they were more likely (4-fold) to receive HD than PD (4). Previous studies have mainly focused on the renal survival or patient survival of AAV before developing ESRD (5–7). Few studies reported the condition of AAV patients needing long-term dialysis after reaching ESRD. In a large cohort study in France, the survival of AAV patients in chronic dialysis did not differ significantly from non-vasculitis patients on dialysis (8). At the same time, researchers of Spain compared the outcomes of different RRT on pauci-immune vasculitis and also reported that dialysis outcome seems equal to other causes of chronic kidney disease (9). Yet, due to the limited sample size, they could not draw a solid conclusion of which RRT modality is better for patients with AAV-ESRD. Up to now, there is no consensus or guideline about which dialysis modality is more suitable for those patients with AAV-ESRD (10).

Thus, we conducted this retrospective cohort study with a larger sample size aiming to compare the difference in patient survival and evaluate the cause of death between HD and PD in a population of ESRD patients secondary to MPO-AAV.

METHODS

Patients

The Hunan Vasculitis Study Group conducted this retrospective study and recruited patients who were diagnosed with AAV-ESRD and needed long-term dialysis from January 2010 to December 2020 in the Department of Nephrology, Xiangya Hospital, and the Third Xiangya Hospital. All patients fulfilled the 2012 Chapel Hill Consensus Conferences Nomenclature of vasculitis and were then classified following the algorithm suggested by the European Medicines Agency in 2007. Exclusion criteria were as follows: (1) eosinophilic granulomatosis with polyangiitis (EGPA) or secondary vasculitis; (2) comorbid kidney diseases, such as IgA nephropathy, membranous nephropathy, diabetic nephropathy, and anti-glomerular basement membrane glomerulonephritis; (3) the coexistence of another autoimmune disease, such as lupus nephritis. The study protocol followed the provisions of the Declaration of Helsinki and was approved by the ethics committees of both hospitals.
Table 1: Baseline characteristics of patients with AAV-ESRD at start of dialysis.

| Variables                      | All patients (n = 85) | Haemodialysis (n = 64, 75%) | Peritoneal dialysis (n = 21, 25%) | P-value |
|--------------------------------|-----------------------|----------------------------|----------------------------------|---------|
| Age, mean ± SD, years          | 59 ± 15               | 62 ± 12                    | 48 ± 17                          | <0.01   |
| Male (%)                       | 36 (42.6%)            | 31 (48.4%)                 | 5 (23.8%)                        | 0.05    |
| Laboratory data, mean ± SD     |                       |                            |                                  |         |
| Serum-creatinine, µmol/L       | 756.6 ± 248.2         | 758.2 ± 257.2              | 752.1 ± 224.4                    | 0.92    |
| Urea-nitrogen, mmol/L          | 26.0 ± 9.8            | 26.0 ± 10.4                | 25.9 ± 7.5                       | 0.99    |
| eGFR, ml/min/1.73 m²           | 6.0 ± 2.3             | 6.0 ± 2.1                  | 6.1 ± 2.7                        | 0.80    |
| White blood cells, 10^9/L      | 8.1 ± 3.3             | 8.2 ± 3.5                  | 7.9 ± 2.6                        | 0.71    |
| Hemoglobin, g/L                | 74 ± 16.1             | 74.2 ± 15.6                | 73.4 ± 18.0                      | 0.84    |
| Platelet, 10^9/L               | 201.9 ± 86.2          | 211.5 ± 92.8               | 173.0 ± 54.1                     | 0.02    |
| ESR, mm/h                      | 68.9 ± 38.8           | 70.9 ± 39.6                | 61.2 ± 35.5                      | 0.38    |
| CRP, mg/dl                     | 9.5 ± 5.8             | 9.8 ± 5.1                  | 9.7 ± 6.0                        | 0.60    |
| Comorbidities, n (%)           |                       |                            |                                  |         |
| CVD                            | 24 (28.2%)            | 13 (20.3%)                 | 11 (52.4%)                       | <0.01   |
| Pulmonary disease              | 12 (14.1%)            | 12 (18.8%)                 | 4 (19.0%)                        | 0.98    |
| Diabetes mellitus              | 6 (7.1%)              | 5 (7.8%)                   | 1 (4.8%)                         | 0.64    |
| Hepatitis                      | 3 (3.5%)              | 1 (1.6%)                   | 2 (9.5%)                         | 0.09    |
| VDI score, mean ± SD           | 1.7 ± 0.7             | 1.7 ± 0.7                  | 1.8 ± 0.7                        | 0.54    |
| Immunosuppressive therapy, n (%)|                     |                            |                                  |         |
| Corticosteroids <7.5 mg/d      | 67 (78.8%)            | 50 (78.1%)                 | 17 (81%)                         | 0.78    |
| 0.3 mg/d                       | 10 (16.1%)            | 3 (5%)                     | 5 (29%)                          | 0.64    |
| Corticosteroids >7.5 mg/d      | 0 (0.0%)              | 0 (0.0%)                   | 0 (0.0%)                         | 0.99    |
| Corticosteroids CYC             | 2 (3.5%)              | 1 (3.5%)                   | 1 (5.4%)                         | 0.98    |
| Overall survival               |                       |                            |                                  |         |
| HD - 1                         | 65.3%                 | 59.6%                      | 59.6%                            | 0.96    |
| PD - 1                         | 98%                   | 90%                        | 90%                              | 67.5%   | 67.5% |

Erythrocyte sedimentation rate; CRP, C-reactive protein; CVD, cardiovascular disease. VDI, Vasculitis Damage Index (range 1–3); CYC, cyclophosphamide.

Overall Survival on Dialysis

The median follow-up of the HD group was 19 months while 30 months of the PD group. During the follow-up, five PD patients switched to hemodialysis and one patient received kidney transplantation and the graft still functions well at the end of observation. No kidney transplantations were performed in the HD group and no HD patient changed to peritoneal dialysis.

Survival rates of AAV-HD at 1, 3, and 5 years were 65.3, 59.6, and 59.6% and 90, 90, and 67.5% of AAV-PD. Almost 50% of AAV-HD patients died in the first three years. The overall survival between the two groups was no significant difference (P = 0.086) at the end of observation (Figure 1). Thirty deaths were recorded. Infection, cardio-cerebrovascular events, and carcinoma were the main causes of death in patients with AAV-ESRD depending on long-term dialysis as shown in Table 2.

Predictors Associated With Mortality

In order to assess factors that could affect the outcome of this study, variables considered clinically important were included in the multivariate model. As shown in Table 3 and Figure 2, there was no difference between HD or PD modality in terms of the survival of patients with AAV-ESRD when adjusted for age, sex, VDI...
score, comorbidities, and drug treatment at the start of dialysis.

**DISCUSSION**

Improvements in induction therapy for AAV have reduced the prevalence of AAV-related ESRD. However, there is little evidence to guide dialysis strategies for patients with AAV-ESRD currently. Therefore, we conducted this study for the sake of obtaining more clinical evidence to determine whether HD or PD is associated with better patient survival. Patients with AAV

| TABLE 2 | Causes of death in patients with AAV-ESRD. |
|----------|---------------------------------------------|
|          | All patients, n = 30 | Haemodialysis, n = 25 | Peritoneal dialysis, n = 5 |
| Infection | 9 (28%) | 5 (20%) | 4 (80%) |
| Heart failure | 10 (31%) | 9 (36%) | 1 (20%) |
| Gastrointestinal hemorrhage | 3 (9%) | 3 (12%) | 0 |
| Hemorrhagic stroke | 4 (13%) | 4 (16%) | 0 |
| Hyperkalemia | 2 (6%) | 2 (8%) | 0 |
| Carcinoma | 2 (6%) | 2 (8%) | 0 |

Results are expressed as n (%).

| TABLE 3 | Predictors for death of AAV-ESRD patient with long-term dialysis. |
|----------|---------------------------------------------------------------|
| Variables | Univariate_cox | Multivariate_cox |
| Age (ref. <50yrs) | 2.6 (0.61-11) | 0.2 |
| Gender (ref. male) | 0.89 (0.43-1.8) | 0.75 |
| Dialysis modality (ref. HD) | 0.53 (0.2-1.4) | 0.19 |
| VDI score | 0.77 (0.45-1.3) | 0.32 |
| Immunosuppression | 1.5 (0.54-3.9) | 0.46 |
| CVD | 0.89 (0.39-2) | 0.78 |
| Pulmonary diseases | 0.74 (0.33-1.7) | 0.48 |
| Diabetes mellitus | 0.25 (0.033-1.9) | 0.18 |

HD, hemodialysis; VDI, Vasculitis Damage Index; CVD, cardiovascular disease.

**FIGURE 2** Hazard ratios for death in AAV-ESRD patient with long-term dialysis. Forest plots show the results of multivariate analysis of predictors at dialysis initiation.

AIC: 386.16; Concordance Index: 0.6

* Event: 55; Global p-value (Log-Rank): 0.85127
The overall survival rate was similar between patients with AAV-HD and with AAV-PD, which was similar to Chen YX's study and the comparative study of patients with SLE-ESRD initiating with PD vs. HD conducted by Contreras G, et al. (14). However, the survival rates of patients with AAV-PD were 90% at 1 year and 68.6% at 5 years, which was higher than survival rates observed by Chen YX, et al. The most plausible explanation is because most patients with AAV-PD in our cohort were much younger (48.4 ± 17.4 vs. 61.2 ± 12.4) as older age has been reported to be an adverse prognostic factor (15, 16).

Infection was the major cause of drop-out and mortality in patients with AAV-PD. Five patients with AAV-PD switched to HD due to refractory peritonitis. No patient with AAV-PD in our cohort experienced relapse during the PD process as one may argue that infection could increase the risk of relapse as SLE did (17, 18). The lower relapse rate in this study was partly due to the ANCA subtype (PR3-ANCA+ patients relapse more than MPO-ANCA+ patients) as our cohorts were MPO-ANCA+ patients and most patients with AAV-PD except one who received kidney transplantation ceased immunosuppression without active extrarenal manifestation of vasculitis after undergoing PD (19, 20).

The present study has several limitations. First, it is a retrospective analysis encompassing 10 years of clinical observation, treatment regimen at induction therapy were not standardized though there is no statistical significance regarding immunosuppressive therapy in this study. Moreover, with the implication of new regimens like rituximab, details of maintenance therapy, and disease flare-up were also needed to be discussed in further prospective cohort studies. Even so, to our knowledge, this study is so far the larger series of long-term follow-up in AAV-ESRD focused on different dialysis modalities.

In conclusion, this study demonstrates that HD and PD are two comparable dialysis modalities for patients with AAV-ESRD.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of both hospitals. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XW, YZ, XX, XA, and HZ designed the study. XW and RT collected and entered data. XW and TM analyzed the data. WN and JS contributed to the data acquisition and interpretation. XW and YZ wrote the original draft. JO, PE, XA, and HZ edited. All authors read and approved the final manuscript.

FUNDING

This work was funded by the National Natural Science Foundation of China (No. 81870498 to HZ and No.81870499 to JS), the National Key R&D Program of China (2020YFC2005000 to XX), the Key Research and Development Program of Hunan province (2018WK2060 to XX and 2020WK2008 to YZ), the science and technology innovation Program of Hunan Province (2020RC5002 to JO), the Natural Science Foundation of Hunan Province (2019JJ40515 to WN), Chinese Society of Nephrology (18020010780 to YZ), the Fundamental Research Funds for the Central Universities of Central South University (2019zzts909 to XW).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.775586/full#supplementary-material

REFERENCES

1. Binda V, Moroni G, Messa P. ANCA-associated vasculitis with renal involvement. J Nephrol. (2018) 31:197–208. doi: 10.1007/s40620-017-0412-z
2. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. (2003) 41:776–84. doi: 10.1016/S0272-6386(03)00025-8
3. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CJ, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. (2005) 143:621–31. doi: 10.7326/0003-4819-143-9-200511010-00005
4. Moiseev S, Novikov P, Jayne D, Mukhin N. End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant. (2017) 32:248–53. doi: 10.1093/ndt/gfw046
5. de Joode AAE, Sanders JSF, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. (2013) 8:1709–17. doi: 10.2215/CJN.01202013
6. Kronichler A, Shin JI, Lee KH, Nakagomi D, Quintana LF, Busch M, et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev. (2020) 19:102495. doi: 10.1016/j.autrev.2020.10.2495
7. Huang L, Zhong Y, Ooi JD, Zhou Y-O, Zuo X, Luo H, et al. The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis. Int Immunopharmacol. (2019) 76:105883. doi: 10.1016/j.intimp.2019.10.5883
8. Romeu M, Coughoud C, Delarozière C, Burtey S, Chiche L, Harlé JR, et al. Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011. QJM. (2014) 107:545–55. doi: 10.1093/qjmed/hcu043
9. Merino JL, Galeano C, Espeso B, Rivera M, Fernández-Lucas M, Caldés S, et al. A retrospective study on outcome of microscopic polyangiitis in
chronic renal replacement therapy. *Nephrol Dial Transplant.* (2011) 26:1360–6. doi: 10.1093/ndt/gfq523
10. Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al. Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. *Kidney Int.* (2019) 95:281–95. doi: 10.1016/j.kint.2018.11.008
11. Lin W, Shen C, Zhong Y, Ooi JD, Eggenhuizen P, Zhou Y-O, et al. Glomerular immune deposition in MPO-ANCA associated glomerulonephritis is associated with poor renal survival. *Front Immunol.* (2021) 12:625672. doi: 10.3389/fimmu.2021.625672
12. Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. *Am J Kidney Dis.* (2020) 75:124–37. doi: 10.1053/j.ajkd.2019.04.031
13. Chen Y-X, Zhang W, Chen X-N, Ni L-Y, Shen P-Y, Wang W-M, et al. Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis. *Clin Exp Rheumatol.* (2014) 32:55–10.
14. Contreras G, Pagan J, Chokshi R, Virmani S, Diego JM, Byers P, et al. Comparison of mortality of ESRD patients with lupus by initial dialysis modality. *Clin J Am Soc Nephrol.* (2014) 9:1949–56. doi: 10.2215/CJN.00480114
15. Li Z-Y, Gou S-J, Chen M, Zhao M-H. Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center. *Semin Arthritis Rheum.* (2013) 42:515–21. doi: 10.1016/j.semarthrit.2012.09.005
16. Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. *Clin J Am Soc Nephrol.* (2015) 10:1128–35. doi: 10.2215/CJN.00480115
17. Lui SL, Lam MF, Tse KC, Lo WK. Reactivation of systemic lupus erythematosus in a dialysis patient after tuberculous peritonitis. *Lupus.* (2002) 11:49–51. doi: 10.1191/0961203302lu096cr
18. Shukla A, Abreu Z, Bargman JM. Streptococcal PD peritonitis—a 10-year review of one centre’s experience. *Nephrol Dial Transplant.* (2006) 21:3545–9. doi: 10.1093/ndt/gfl407
19. Tieu J, Smith R, Basu N, Brogan P, D'Cruz D, Dhaun N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. *Rheumatology (Oxford).* (2020) 59:e24–32. doi: 10.1093/rheumatology/kez640
20. Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. *Kidney Int.* (2009) 76:644–51. doi: 10.1038/ki.2009.218

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wu, Zhong, Meng, Ooi, Eggenhuizen, Tang, Nie, Xiao, Sun, Ao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.